Product Description
Lonafarnib is an oral, small molecule inhibitor of farnesyltransferase that is used to treat Hutchison-Gilford progeria syndrome and is under investigation as therapy of chronic hepatitis D. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Lonafarnib)
Mechanisms of Action: FT Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Belgium | Croatia | Czech | European Medicines Agency | Finland | Germany | Hungary | Iceland | Ireland | Israel | Italy | Latvia | Lithuania | Poland | Portugal | Slovakia | Sweden | United States
Approved Indications: None
Known Adverse Events: None
Company: Eiger BioPharmaceuticals
Company Location: PALO ALTO CA 94306
Company CEO: David A. Cory
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Hepatocellular Carcinoma|Liver Cirrhosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| D-LIVR | P3 |
Completed |
Liver Cirrhosis|Hepatocellular Carcinoma |
2023-03-24 |
2025-05-06 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
09/25/2024 |
News Article |
Septerna Marks Transition to a Clinical-Stage Company with Appointments of Industry Veterans in Key Drug Development Roles |
|
05/03/2024 |
News Article |
Sentynl Therapeutics Announces Global Acquisition of Zokinvy® (Lonafarnib) for Treatment of Hutchinson-Gilford Progeria Syndrome from Eiger BioPharmaceuticals |
|
04/01/2024 |
News Article |
Eiger BioPharmaceuticals Files for Voluntary Chapter 11 Protection |
|
03/26/2024 |
News Article |
The Progeria Research Foundation Selected as an Official Charity Partner in 2024 Boston Marathon |